HBM Healthcare Investments Reports Robust Growth in 2025 Despite Currency Challenges

HBM Healthcare Investments, a company focused on the healthcare sector, reported a successful performance in 2025. The net asset value (NAV) saw an increase of 14.8% in Swiss francs and 31.4% in US Dollars, accompanied by a 33% rise in share price. This growth outpaced key market indices such as the NASDAQ Biotechnology Index and the MSCI World Healthcare Index.

The positive performance stemmed from its investment strategy, balancing investments in both private and publicly listed companies. Notable exits from Swixx Biopharma and Dren Bio contributed significantly. Renewed interest in the biotechnology sector further boosted publicly listed companies.

Despite these achievements, the appreciation of the Swiss franc against major currencies negatively impacted results. For the first nine months of the 2025/2026 financial year, HBM forecasted a noteworthy profit of CHF 286 million, up from CHF 66 million.